We are now in the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of dementia.
Frontiers has organized a series of Research Topics to highlight the latest advancements in research across the field of dementia, with articles from important researchers in dementia research. This editorial initiative of particular relevance is led by Prof. Zoe Arvanitakis and Prof. Charbel Moussa, Specialty Chief Editors of the “Aging and Risk Factors for Dementia” section and the "Translational Research in Dementia" section, respectively, together with Prof. Kejal Kantarci and Prof. Brendan McCormack, and it is focused on new insights, novel developments, current challenges, latest discoveries, recent advances, and future perspectives in the field of dementia.
The Research Topic solicits forward-looking contributions from the invited contributors that describe the state-of-the-art research, outlining recent developments and major accomplishments that have been achieved and that need to occur to move the field forward, as well as ongoing research that will help shed light on key questions in the field. Authors are encouraged to identify the greatest challenges in the sub-disciplines, and how to address those challenges.
The goal of this Research Topic special edition is to shed light on the progress made in the past decade in the dementia field, on current research and its future challenges to provide a thorough overview of the field. This article collection will inspire, inform, and provide direction and guidance to researchers in the field.
This collection is on invitation only and will contain original research and review articles.
Articles accepted after peer review will be published and appear online as soon as accepted for publication.
Dr. Charbel Moussa has received research funding from SUN Pharma Advanced Research Company and KeifeRX for research on drug development in dementia. Dr. Moussa also received research funding from SKybio and NIA for research on drug development in dementia and is co-inventor of several Georgetown University patents related to dementia treatment. Dr. Zoe Arvanitakis has received funds in the last year for consulting from the following for-profit entities: Eisai, and Summus Global. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Article types and fees
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Brief Research Report
Case Report
Classification
Clinical Trial
Data Report
Editorial
FAIR² Data
FAIR² DATA Direct Submission
General Commentary
Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.
Article types
This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:
Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.